ten bagger plus?, page-2

posted about clinical trials earlier today.. this is the list of clinical trials that ISN is involved in USA.

http://ClinicalTrials.gov/ct2/results?spons=%22KarmelSonix+Ltd.%22&spons_ex=Y

ones in the midst of ending. there are two scheduled for next year.

the following is an article by proactiveinvestor:


iSonea (ASX: ISN) is focused on securing a major strategic partner to launch, distribute and sell its Acoustic Respiratory Monitoring® products in the U.S. and other key asthma markets as it ramps up towards commercialisation.

The company is in negotiations with several major strategic partner candidates for development and distribution of its products.

Another core objective of iSonea’s commercialisation plan is developing over-the-counter asthma monitoring devices with mobile health capabilities, using iSonea core technology coupled with internet and social media marketing campaigns.

This will lower production costs and should increase sales and distribution capacity.

iSonea also plans to conduct short-duration clinical studies in the U.S. to enable insurance reimbursement for iSonea products.

http://www.proactiveinvestors.com.au/companies/news/22626/isonea-accelerates-commercialisation-of-asthma-devices-in-us-in-negotiations-with-partners--22626.html



iSonea also plans to conduct short-duration clinical studies in the U.S. to enable insurance reimbursement for iSonea products.

results from all the above clinical trials would facilitate ISN moving from CPT III to CPT I enabling a more steady reimbursement.. positive results will help move sp..


blokes i reckon if ISN concludes a deal with a big player in US for a strategic alliance (ie Philips et al), it would surely propel ISN to at least ~50million MC..